BioRestorative Therapies (BioRestorative Therapies) Cash-to-Debt : 68.31 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. BioRestorative Therapies's cash to debt ratio for the quarter that ended in Dec. 2023 was 68.31.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, BioRestorative Therapies could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for BioRestorative Therapies's Cash-to-Debt or its related term are showing as below:

BRTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.13 Max: 68.31
Current: 68.31

During the past 13 years, BioRestorative Therapies's highest Cash to Debt Ratio was 68.31. The lowest was 0.02. And the median was 0.13.

BRTX's Cash-to-Debt is ranked better than
76.14% of 1538 companies
in the Biotechnology industry
Industry Median: 6.485 vs BRTX: 68.31

BioRestorative Therapies Cash-to-Debt Historical Data

The historical data trend for BioRestorative Therapies's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

BioRestorative Therapies Cash-to-Debt Chart

BioRestorative Therapies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.64

31.34

49.00

68.31

BioRestorative Therapies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															49.00	46.00	49.64	61.81	68.31

Competitive Comparison of BioRestorative Therapies's Cash-to-Debt

For the Biotechnology subindustry, BioRestorative Therapies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioRestorative Therapies's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's Cash-to-Debt falls into.

BioRestorative Therapies Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

BioRestorative Therapies's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	11.066	/	(0.162	+	0)
	=	68.31

BioRestorative Therapies's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	11.066	/	(0.162	+	0)
	=	68.31

BioRestorative Therapies (NAS:BRTX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

BioRestorative Therapies Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of BioRestorative Therapies's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BioRestorative Therapies (BioRestorative Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (NAS:BRTX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

9OF:Germany

Address

40 Marcus Drive, Suite One, Melville, NY, USA, 11747

Website

https://www.biorestorative.com

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

Executives

Dale Broadrick	10 percent owner	3003 BRICK CHURCH PIKE, NASHVILLE TN 37207
Lance Alstodt	director, 10 percent owner, officer: President, CEO, COB	BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Francisco Silva	director, 10 percent owner, officer: VP of Research and Development	STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Robert Eugene Kristal	officer: Chief Financial Officer	4719 COLE AVENUE, DALLAS TX 75205
Patrick F. Williams	director	C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
David A Rosa	director	10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Nickolay V. Kukekov	director	4524 WESTWAY AVE, DALLAS TX 75205
Mark Weinreb	director, 10 percent owner, officer: CEO and Chairman of the Board	STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Paul Jude Tonna	director	69 CHICHESTER ROAD, HUNTINGTON NY 11743
A. Jeffrey Radov	director	8 WALWORTH AVENUE, SCARSDALE NY 10583
Robert Paccasassi	officer: VP, Quality and Compliance	C/O BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Robert B Catell	director	62 OSBORNE ROAD, GARDEN CITY NY 11530
Adam D. Bergstein	officer: SVP, Planning and Business Dev	167 HAZEL AVENUE, GLENCOE IL 60022
John M Desmarais	director	230 PARK AVENUE, NEW YORK NY 10169
Westbury Trust	10 percent owner	VICTORIA HALL, 11 VICTORIA STREET, P.O. BOX HM 1065, HAMILTON D0 00000